Guangcui He
Chengdu, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Comparison of Allo-HSCT outcomes after CAR-T therapy versus chemotherapy in pediatric patients with relapsed/refractory B-ALL: a retrospective study.
Journal: The oncologist
Published: October 31, 2025
Triple stem cell infusion alleviated graft-versus-host disease and improves outcomes in unmanipulated haploidentical hematopoietic stem cell transplantation.
Journal: Cell transplantation
Published: July 25, 2025
A retrospective study of an irradiation-based conditioning regimen and chidamide maintenance therapy in T-ALL/LBL.
Journal: Hematology (Amsterdam, Netherlands)
Published: May 22, 2024
Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission.
Journal: Frontiers in immunology
Published: February 21, 2024
Treatment of CML-transformed B Cell Acute Lymphoblastic Leukemia (B-ALL) in Adults with Anti-CD19 Chimeric Antigen Receptor T Cell (CAR T) Therapy.
Journal: Stem cell reviews and reports
Published: August 26, 2020
Infusion of basic fibroblast growth factor ameliorates acute graft versus host disease in mice after haploidentical hematopoietic stem cell transplantation.
Journal: Immunology letters
Published: July 31, 2015
Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia.
Journal: The international journal of biochemistry & cell biology
Published: November 14, 2014
Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells.
Journal: European journal of haematology
Published: September 06, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026